New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders
Kibret, Berhanu Geresu, Ishiguro, Horiuchi, Onaivi, Emmanuel S., Berhanu Geresu Kibret, Hiroki Ishiguro, Yasue Horiuchi, Emmanuel S. Onaivi
Indeed, the densities of eCB receptors and the levels of eCBs have been suggested as possible biomarkers in neuropsychiatric disorders [ 75 ]. A study to evaluate the expression of CB1R and CB2R in the hippocampus showed that maternal deprivation induced a significant increase in CB2R immunoreactivity in the hippocampal areas, indicating the possible involvement of CB2Rs in neurodevelopmental mental illnesses such as schizophrenia [ 86 ]. Furthermore, in these mutant−/− mice, treatment with the antipsychotic risperidone normalized the PPI readings [ 56 90 ]. Interestingly another study showed that CB2R is required for the antipsychotic effects of acetylcholine muscarinic 4 (M4) receptor agonists like UV0467154 [ 91 ]. As a result, inhibiting CB2Rs with the antagonist AM630 would prevent the antipsychotic effects of M4 agonists.
Tags:
- Cannabinoid receptor type 2
- Experimental autoimmune encephalomyelitis
- Schizophrenia
- Cannabinoid receptor
- Neurodegenerative disease
- Addiction
- Microglia
- Neuroinflammation
- Endocannabinoid system
- Depression (mood)
- Substantia nigra
- Diseases and disorders
- Medical specialties
- Biochemistry
- Health
- Clinical medicine
- Neuroscience